Bio-Rad Laboratories Inc. (BIO)
BIO trades on NYSE in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/12208/000001220826000010/0000012208-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BIO on NYSE |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 1980 |
| SEC CIK | 0000012208 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.6B |
| Net income | $759.9M |
| Operating income | $47.2M |
| Net margin | 29.4% |
| Operating margin | 1.8% |
| Revenue growth | +0.7% |
| Cash | $529.8M |
| Total assets | $10.6B |
| P/E (computed) | 12.7× |
| P/S (computed) | 3.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $465.3M cash; operating cash flow $117.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 26,892,945 (2026-10-30); 26,974,835 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Santa Clara, California, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $350K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $656.4M | $458.6M | $96.4M | $465.3M | $1.2B | $2.6B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $651.0M | $371.4M | $98.7M | $517.0M | $1.2B | $2.6B | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $592.1M | -$527.1M | $108.1M | $507.2M | $1.2B | $2.6B | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $693.2M | $720.0M | $164.9M | $529.8M | $1.2B | $2.6B | 10-K 2026-02-13 |
| Q3 2025 2025-09-30 | $653.0M | -$341.9M | $120.9M | $395.8M | $1.2B | $2.6B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $651.6M | $317.8M | $116.5M | $369.3M | $1.2B | $2.6B | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $585.4M | $64.0M | $129.9M | $521.4M | $1.2B | $2.5B | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $667.5M | -$715.8M | $124.2M | $488.1M | $1.2B | $2.6B | 10-K 2026-02-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2022-02-25 |
| Latest annual report | 10-K | 2026-02-13 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-03-25 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.0% |
| 1 month | +0.7% |
| 3 months | +1.4% |
| Year to date | +20.9% |
| 1 year | +15.6% |
| From 52-week high | -6.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BIO/B | Bio-Rad Laboratories Inc. | $377.29 |
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BRKR | Bruker Corporation | $60.62 | -1.57% | $9.3B |
| AVTR | Avantor Inc. | $15.32 | -1.42% | $10.4B |
| TXG | 10x Genomics Inc. | $54.99 | -5.50% | $7.2B |
| RVTY | Revvity Inc. | $148.85 | -3.59% | $16.6B |
| MTD | Mettler-Toledo International Inc. | $1727.26 | -0.67% | $34.4B |
| ALMR | Alamar Biosciences Inc. | $30.55 | -0.84% | $2.1B |
| WAT | Waters Corporation | $453.42 | -1.48% | $44.6B |
| A | Agilent Technologies Inc. | $172.92 | -0.60% | $48.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier